Episodios

  • Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)

    Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)
    Mar 2 2021

    Professors Marc Fisher and Liping Liu discuss the CHANCE and PRINCE clinical trials focusing on their backgrounds and key results, and commenting on their clinical implications.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Más Menos
    18 m
  • Discussion on the POINT trial (with Marc Fisher and Greg Albers)

    Discussion on the POINT trial (with Marc Fisher and Greg Albers)
    Mar 2 2021

    Professor Marc Fisher and Dr Greg Albers discuss the POINT trial, also commenting on when to consider ticagrelor versus clopidogrel.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Más Menos
    18 m
  • Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

    Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
    Mar 2 2021

    Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Más Menos
    22 m